Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer that has spread to other parts of your body and your tumor is measurable.
- You have had only one prior treatment for this cancer that included oxaliplatin, a fluoropyrimidine, and bevacizumab.
- Your cancer does not have certain genetic features (MSI-H or BRAF V600 mutation).
- You are at least 18 years old and able to care for yourself (ECOG score 0 to 2).
- You have not had FOLFIRI or irinotecan before, and you haven't had surgery within the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial is testing a combination of two oral anti-cancer drugs (fruquintinib and S-1) for people whose metastatic colorectal cancer has not responded to at least two standard treatments. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests if a newer targeted drug (fruquintinib) works as well as a standard drug (bevacizumab) when combined with two chemotherapy drugs for people with advanced colorectal cancer that got worse after first treatment. It aims to find a better option for second-line treatment.
This trial tests a combination of two drugs (QL1706 and fruquintinib) for people with a specific type of advanced colorectal cancer (MSS/pMMR) that has stopped responding to at least two prior treatments. If your tumor has certain immune markers, this approach may help your body fight the cancer more effectively.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.